UTAH MEDICAL PRODUCTS INC

Form 8-K December 10, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 7, 2012

Commission File No. 0-11178

UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter)

UTAH (State or other jurisdiction of incorporation or organization)

87-0342734 (I.R.S. Employer Identification No.)

7043 South 300 West Midvale, Utah 84047 Address of principal executive offices

Registrant's telephone number: (801) 566-1200

Edgar Filing: UTAH MEDICAL PRODUCTS INC - Form 8-K

ITEM 1.01 Entry Into a Material Definitive Agreement

On December 7, 2012, Utah Medical Products, Inc. (UTMD) and JPMorgan Chase Bank, N.A. (Chase) modified the loan agreement they entered into on March 17, 2011 and subsequently amended on September 23, 2011. This second amendment reduces the monthly principal payment to \$116,666.67 from \$233,333.33. The 50% reduction is needed because UTMD has paid off \$9.3 million of the \$14.0 million initial loan amount in the first 20 months of the 5 year loan. A copy of the modification agreement is attached hereto as Exhibit 1.

ITEM 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

(d) Exhibits

SEC

Exhibit Reference

Title of Document

111

Second Modification Agreement dated as of December 7, 2012 among Utah Medical Products, Inc., as Borrower, and JPMorgan Chase Bank, N.A., as Lender

Edgar Filing: UTAH MEDICAL PRODUCTS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UTAH MEDICAL PRODUCTS, INC. REGISTRANT

Date: 12/10/2012 By: /s/ Kevin L. Cornwell

Kevin L. Cornwell

CEO